CNR1 and neoplasm: An increase in CB2R expression in the tumor has been linked to increased aggressiveness and recurrence risk in breast, prostate, pancreas, thyroid and colon cancer, whereas the relationship between CB1 expression and tumor progression is less clear (Pagano et al., 2021).